Prurigo Nodularis Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Prurigo Nodularis Treatment Market is segmented By Product type (Corticosteroids, Anti-histamines, Emollients, Capsaicin cream, Others), By End-user (Hospital pharmacies, Retail pharmacies, Online pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Prurigo Nodularis Treatment Market Overview

The Global Prurigo Nodularis Treatment Market reached USD 964.3 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1.1 billion by 2030. The Global Prurigo Nodularis Treatment Market is exhibiting at a CAGR of 3.7% during the forecast period 2023-2030. Prurigo nodularis is a chronic skin condition characterized by intensely itchy nodules or bumps.

Treatment options include topical steroids, immune modulators, capsaicin cream, antihistamines, systemic medications, and phototherapy. Market dynamics are influenced by the prevalence of the condition, availability of treatment options, and geographical distribution of affected individuals. 

The prurigo nodularis treatment market is driven by factors such as the increasing prevalence of prurigo nodularis, increasing demand for capsaicin cream, advancements and innovations in treatment options, increasing adoption of emollients, growing interest in targeted therapies and biologics, and technological advancements. Limited treatment options and the high cost of the treatment are the major market restraints.

Prurigo Nodularis Treatment Market Scope

To know more insights - Download Sample

Prurigo Nodularis Treatment Market Dynamics

Increasing Demand for Capsaicin Cream

The increasing demand for capsaicin cream is a major factor driving the market share during the forecast period. Capsaicin cream has been shown to provide effective relief from itching, which is one of the primary symptoms of prurigo nodularis. Capsaicin works by desensitizing the nerve fibers that transmit itch signals, thereby reducing the sensation of itching and providing relief to patients.

For instance, in cases where individuals with prurigo nodularis cannot tolerate or prefer to avoid corticosteroids, capsaicin creams can provide a non-steroidal alternative for managing itching and inflammation.

Limited Treatment Options

The limited treatment options for prurigo nodularis are a major factor expected to hamper the market growth during the forecast period. Despite ongoing research, the treatment options for prurigo nodularis are still limited, particularly in severe or refractory cases. The lack of effective therapies can hinder market growth and leave patients with limited options for symptom management.

Limited treatment options can create challenges for healthcare providers in effectively managing prurigo nodularis. It may require a trial-and-error approach to find the most suitable treatment regimen for each patient, which can be time-consuming and costly. Moreover, healthcare providers may feel frustrated when they are unable to offer optimal care due to the lack of effective treatment options.

For more details on this report –Request for Sample

Prurigo Nodularis Treatment Market Segment Analysis

The Global Prurigo Nodularis Treatment Market is segmented based on product, distribution channel, and region.

Based on the Product, the Corticosteroids Segment is Expected to Dominate the Market Share 

The corticosteroids segment is expected to dominate the market share during the forecast period based on the disease type. The market for corticosteroids holds 35.6% of the market share in 2022. Corticosteroids, such as topical creams or ointments, are commonly prescribed as a first-line treatment for prurigo nodularis due to their anti-inflammatory properties. They are applied directly to the affected skin areas to reduce inflammation and alleviate itching. 

Corticosteroids have been extensively studied and used in clinical practice for many years. Their efficacy and safety profile in the management of prurigo nodularis has been established, contributing to their widespread use and acceptance by healthcare professionals. Examples of topical corticosteroids include hydrocortisone, betamethasone, and clobetasol.

Source: DataM Intelligence Analysis (2023)

Prurigo Nodularis Treatment Market Geographical Penetration

North America Holds the Largest Market Share Due to the Large Patient Population and Advanced Healthcare Infrastructure

North America holds the largest market of around 42.7% market share for the prurigo nodularis treatment market in 2022. Prurigo nodularis is common in North America, and the region has a significant patient population affected by the condition. The high prevalence of prurigo nodularis in North America creates a demand for effective treatment options, driving market growth.

The well-developed healthcare information systems and patient education initiatives in North America contribute to increased awareness of prurigo nodularis among patients and healthcare providers. With higher awareness, patients are more likely to seek appropriate treatment, leading to a larger market share.

Source: DataM Intelligence Analysis (2023)

Prurigo Nodularis Treatment Market Players

The major global players include Menlo Therapeutics Inc., Pfizer Inc, Sanofi S.A., Kiniksa Pharmaceuticals Ltd., Astellas Pharma Inc, Eli Lilly and Company, GlaxoSmithKline, Galderma S.A., Trevi Therapeutics Inc, and Regeneron Pharmaceuticals Inc.

COVID-19 Impact on Prurigo Nodularis Treatment Market

During the pandemic, healthcare systems worldwide experienced disruptions and reallocation of resources to manage the influx of COVID-19 patients. Non-urgent or elective dermatology appointments and procedures were often postponed or canceled, affecting the diagnosis and treatment of prurigo nodularis. This disruption may have led to delays in initiating or adjusting treatment plans for patients with prurigo nodularis.

Lockdowns, travel restrictions, and social distancing measures during the pandemic limited patient access to healthcare facilities. Patients with prurigo nodularis may have faced challenges in seeking medical attention, obtaining regular follow-ups, or accessing specialized dermatology care. This could have impacted the timely diagnosis, treatment initiation, and overall management of prurigo nodularis.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war significantly impacted the prurigo nodularis treatment market growth. The conflict can disrupt global supply chains, including the production and distribution of medications and dermatological products used in the treatment of prurigo nodularis. This can lead to shortages or delays in the availability of these treatments in markets.

In regions directly affected by the conflict, there may be a migration of healthcare professionals, including dermatologists and researchers, seeking stability and better opportunities elsewhere. This can potentially impact the global pool of specialized healthcare providers available for prurigo nodularis treatment and research.

By Product

• Corticosteroids
• Anti-Histamines
• Emollients
• Capsaicin Cream
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In March 2023, Galderma, a Swiss pharmaceutical company, announced that it had completed three phases III clinical trials studying nemolizumab, a first-in-class investigational monoclonal antibody directed against the IL-31 receptor alpha with a central role in pruritus (itch) and skin inflammation, in the treatment of prurigo nodularis and atopic dermatitis.
• In January 2023, Lululab, an artificial intelligence-based healthcare analysis company in South Korea, partnered with Hancom Care Link, a digital healthcare platform operator specializing in gene analysis, to develop a smart skincare analysis platform. The platform with various skin data with patients' different physical features will be provided to medical centers associated with Hancom Care Link. 

Why Purchase the Report?

• To visualize the Global Prurigo Nodularis Treatment Market segmentation based on product, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of Prurigo Nodularis Treatment Market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Prurigo Nodularis Treatment Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceuticals related reports, please click here